|Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma|
TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ...
New England Journal of Medicine 361 (10), 947-957, 2009
|Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study|
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ...
The Lancet 374 (9699), 1432-1440, 2009
|Lung cancer: current therapies and new targeted treatments|
FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran Jr, YL Wu, ...
The Lancet 389 (10066), 299-311, 2017
|Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …|
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
|The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia|
YJ Wu, LM Parker, NE Binder, MA Beckett, JH Sinard, CT Griffiths, ...
Cell 31 (3), 693-703, 1982
|Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …|
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
|Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3|
TL Cha, BP Zhou, W Xia, Y Wu, CC Yang, CT Chen, B Ping, AP Otte, ...
science 310 (5746), 306-310, 2005
|The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer|
R Rami-Porta, V Bolejack, J Crowley, D Ball, J Kim, G Lyons, T Rice, ...
Journal of Thoracic Oncology 10 (7), 990-1003, 2015
|Challenges to effective cancer control in China, India, and Russia|
PE Goss, K Strasser-Weippl, BL Lee-Bychkovsky, L Fan, J Li, ...
The lancet oncology 15 (5), 489-538, 2014
|Global cancer surgery: delivering safe, affordable, and timely cancer surgery|
R Sullivan, OI Alatise, BO Anderson, R Audisio, P Autier, A Aggarwal, ...
The lancet oncology 16 (11), 1193-1224, 2015
|Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 …|
JC Soria, YL Wu, K Nakagawa, SW Kim, JJ Yang, MJ Ahn, J Wang, ...
The Lancet Oncology 16 (8), 990-998, 2015
|A new small (40 kd) keratin filament protein made by some cultured human squamous cell carcinomas|
YJ Wu, JG Rheinwald
Cell 25 (3), 627-635, 1981
|Zinc(II)‐Selective Ratiometric Fluorescent Sensors Based on Inhibition of Excited‐State Intramolecular Proton Transfer|
MM Henary, Y Wu, CJ Fahrni
Chemistry–A European Journal 10 (12), 3015-3025, 2004
|A fast algorithm for 2-D direction-of-arrival estimation|
Y Wu, G Liao, HC So
Signal processing 83 (8), 1827-1831, 2003
|Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study|
TE Ciuleanu, T Brodowicz, CP Belani, J Kim, M Krzakowski, E Laack, ...
Journal of Clinical Oncology 26 (15_suppl), 8011-8011, 2008
|Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non …|
JS Ahn, YC Ahn, JH Kim, CG Lee, EK Cho, KC Lee, M Chen, DW Kim, ...
Journal of Clinical Oncology 33 (24), 2660-2666, 2015
|Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)|
CP Belani, T Brodowicz, T Ciuleanu, JH Kim, M Krzakowski, E Laack, ...
Journal of Clinical Oncology 27 (18_suppl), CRA8000-CRA8000, 2009
|The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming …|
FC Detterbeck, K Chansky, P Groome, V Bolejack, J Crowley, ...
Journal of thoracic oncology 11 (9), 1433-1446, 2016
|Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy|
B Coudert, T Ciuleanu, K Park, YL Wu, G Giaccone, W Brugger, ...
Annals of oncology 23 (2), 388-394, 2012
|Lecture notes on information theory|
Y Polyanskiy, Y Wu
Lecture Notes for ECE563 (UIUC) and 6 (2012-2016), 7, 2014